- About Journal
- Literature browse
- For Authors
- For Reviewers
- News and Events
- Personal Center
- Logout
FOLLOWUS
- About Journal
- Literature browse
- For Authors
- For Reviewers
- News and Events
- Share with wechat friends or circle of friends
Anesthesia Management in Hereditary Pheochromocytoma and Paraganglioma: Updated Insights into Clinical Features and Perioperative Care
- Affiliations：
1.Department of Anesthesiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medicine Science, Beijing 100730, China.
2.State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medicine Science, Beijing 100730, China
- Author bio：
E-mail: pumchshenle@163.com.
- Funds：
DOI：10.24920/004360
CLC：Published：30 September 2024，
Published Online：30 August 2024，
Received：25 March 2024，
Accepted：2024-06-26
- Accepted：
Scan QR Code
李瑶函,申乐.遗传性嗜铬细胞瘤和副神经节瘤的麻醉管理：临床特点和围术期新知[J]. 中国医学科学杂志（英文）,2024,39(03):211-216.
Li Yao-Han,Shen Le.Anesthesia Management in Hereditary Pheochromocytoma and Paraganglioma: Updated Insights into Clinical Features and Perioperative Care[J].Chinese Medical Sciences Journal,2024,39(03):211-216.
李瑶函,申乐.遗传性嗜铬细胞瘤和副神经节瘤的麻醉管理：临床特点和围术期新知[J]. 中国医学科学杂志（英文）,2024,39(03):211-216. DOI： 10.24920/004360.
Li Yao-Han,Shen Le.Anesthesia Management in Hereditary Pheochromocytoma and Paraganglioma: Updated Insights into Clinical Features and Perioperative Care[J].Chinese Medical Sciences Journal,2024,39(03):211-216. DOI： 10.24920/004360.
摘要
约40%的嗜铬细胞瘤和副神经节瘤（pheochromocytoma and paraganglioma，PPGL）属于遗传性疾病，其发病更早，临床表现更为复杂。本文通过回顾遗传性PPGL的相关文献及指南，旨在为临床诊治提供帮助。希佩尔-林道（von Hippel-Lindau，VHL）病中虽然嗜铬细胞瘤的分泌功能更强，但围术期血流动力学无明显变化。2型多发性内分泌腺瘤病（multiple endocrine neoplasias type 2，MEN2）中的嗜铬细胞瘤分泌功能更强，术中血流动力学波动明显。因此，在 MEN2 的所有阶段均应筛查嗜铬细胞瘤。1型神经纤维瘤（neurofibromatosis type 1，NF1）通常并发多系统病变且可能存在困难气道，当NF1患者出现高血压时应筛查嗜铬细胞瘤。家族性副节瘤综合征可能合并多发的嗜铬细胞瘤或副神经节瘤。总之，遗传性 PPGL 通常合并其他系统的严重病变，围术期的多学科团队（multidisciplinary team，MDT）合作在临床诊疗中通常更有意义。
Abstract
Approximately 40% of pheochromocytoma and paraganglioma (PPGL) cases are familial
typically presenting earlier with more complex symptoms. This paper synthesizes literature and guidelines to inform on clinical characteristics and perioperative care for PPGL. Pheochromocytoma in von Hippel-Lindau (VHL) disease exhibits heightened secretion activity without significant perioperative hemodynamic changes. Tumors in multiple endocrine neoplasia type 2 (MEN2) have a stronger endocrine function
which may induce hemodynamic fluctuations during surgery. Therefore
pheochromocytoma screening is essential at all stages of MEN2. Neurofibromatosis type 1 (NF1) often presents multisystem lesions and can result in difficult airway. Pheochromocytoma should be evaluated when NF1 patients present hypertension. Pheochromocytoma and paraganglioma type 5 may present multiple lesions of pheochromocytoma or paraganglioma. In summary
hereditary PPGLs may present with severe lesions in other systems
beyond tumor function. A multi-disciplinary team (MDT) approach is often invaluable in perioperative management.
关键词
嗜铬细胞瘤副神经节瘤遗传性疾病麻醉管理血流动力学
Keywords
pheochromocytomaparagangliomagenetic diseaseanesthetic managementhemodynamicperioperative care
references
Neumann HPH, Young WF, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med 2019; 381(6): 552-65. doi:10.1056/NEJMra1806651http://dx.doi.org/10.1056/NEJMra1806651.
Torresan F, Beber A, Schiavone D, et al. Long-term outcomes after surgery for pheochromocytoma and sympathetic paraganglioma. Cancers (Basel) 2023; 15(11): 2890. doi: 10.3390/cancers15112890http://dx.doi.org/10.3390/cancers15112890.
Benn DE, Robinson BG, Clifton-Bligh RJ. 15 years of paraganglioma: clinical manifestations of paraganglioma syndromes types 1–5. Endocr-Relat Cancer 2015; 22(4): T91-T103. doi:10.1530/erc-15-0268http://dx.doi.org/10.1530/erc-15-0268.
Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99(6): 1915-42. doi:10.1210/jc.2014-1498http://dx.doi.org/10.1210/jc.2014-1498.
Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol 2021; 23(10): 1995-2019. doi:10.1007/s12094-021-02622-9http://dx.doi.org/10.1007/s12094-021-02622-9.
Neumann HP, Young WF, Krauss T, et al. 65 years of the double helix: genetics informs precision practice in the diagnosis and management of pheochromocytoma. Endocr Relat Cancer 2018; 25(8): T201-T19. doi:10.1530/erc-18-0085http://dx.doi.org/10.1530/erc-18-0085.
von Dobschütz E, Neumann HPH. Genetik von phäochromozytomen und ihre bedeutung in der chirurgie. Chirurg 2019; 90(1): 15-22. doi:10.1007/s00104-018-0741-zhttp://dx.doi.org/10.1007/s00104-018-0741-z.
Lima JV, Scalissi NM, de Oliveira KC, et al. Germline genetic variants in pheochromocytoma/paraganglioma: single-center experience. Endocr Oncol 2023; 3(1): e220091. doi:10.1530/eo-22-0091http://dx.doi.org/10.1530/eo-22-0091.
Buffet A, Burnichon N, Favier J, et al. An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab 2020; 34(2): 101416. doi:10.1016/j.beem.2020.101416http://dx.doi.org/10.1016/j.beem.2020.101416.
Lenders JWM, Kerstens MN, Amar L, et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 2020; 38(8): 1443-56. doi:10.1097/hjh.0000000000002438http://dx.doi.org/10.1097/hjh.0000000000002438.
Abedalthagafi M. Commentary: von hippel–lndau disease: a clinical and scientific review. Eur J Hum Genet 2022; 30(10): 1103-4. doi:10.1038/s41431-022-01172-0http://dx.doi.org/10.1038/s41431-022-01172-0.
Li SR, Nicholson KJ, McCoy KL, et al. Clinical and biochemical features of pheochromocytoma characteristic of von hippel-Lindau syndrome. World J Surg 2020; 44(2): 570-7. doi:10.1007/s00268-019-05299-yhttp://dx.doi.org/10.1007/s00268-019-05299-y.
Aufforth RD, Ramakant P, Sadowski SM, et al. Pheochromocytoma screening initiation and frequency in von Hippel-Lindau syndrome. J Clin Endocrinol Metab 2015; 100(12): 4498-504. doi:10.1210/jc.2015-3045http://dx.doi.org/10.1210/jc.2015-3045.
Welander J, Söderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 2011; 18(6): R253-76. doi:10.1530/erc-11-0170http://dx.doi.org/10.1530/erc-11-0170.
Ercan M, Kahraman S, Başgül E, et al. Anaesthetic management of a patient with von Hippel-Lindau disease: a combination of bilateral phaeochromocytoma and spinal cord haemangioblastoma. Eur J Anaesthesiol 1996 ;13 1: 81-3 doi:10.1097/00003643-199601000-00014http://dx.doi.org/10.1097/00003643-199601000-00014.
Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003; 361(9374): 2059-67. doi: 10.1016/S0140-6736(03)13643-4http://dx.doi.org/10.1016/S0140-6736(03)13643-4.
Daniels AB, Tirosh A, Huntoon K, et al. Guidelines for surveillance of patients with von hippel-lindau disease: consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer 2023; 129(19): 2927-40 .doi:10.1002/cncr.34896http://dx.doi.org/10.1002/cncr.34896.
Eisenhofer G, Walther MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001; 86(5): 1999-2008. doi:10.1210/jcem.86.5.7496http://dx.doi.org/10.1210/jcem.86.5.7496.
Wang L, Feng Y, Jiang LY. Anesthetic management of bilateral pheochromocytoma resection in von Hippel-Lindau syndrome: a case report. World J Clin Cases 2021; 9(15): 3711-5. doi:10.12998/wjcc.v9.i15.3711http://dx.doi.org/10.12998/wjcc.v9.i15.3711.
McCarthy T, Leighton R, Mushambi M. Spinal anaesthesia for caesarean section for a woman with von Hippel-Lindau disease. Int J Obstet Anesth 2010; 19(4): 461-2. doi: 10.1016/j.ijoa.2010.03.015http://dx.doi.org/10.1016/j.ijoa.2010.03.015.
Lye S, Au Yong APS. Anesthetic challenge in a parturient with von Hippel-Lindau disease. Cureus 2023; 15(11): e49749. doi:10.7759/cureus.49749http://dx.doi.org/10.7759/cureus.49749.
Burnette MS, Mann TS, Berman DJ, et al. Brain tumor, pheochromocytoma, and pregnancy: a case report of a cesarean delivery in a patient with von Hippel-Lindau disease. A A Pract 2019; 13(8): 289-91. doi:10.1213/xaa.0000000000001049http://dx.doi.org/10.1213/xaa.0000000000001049.
Yap A, Hanada S, Ravindranath S, et al. Thoracic epidural analgesia in a patient with von Hippel-Lindau disease. Clin Case Rep 2022; 10(3): e05629. doi:10.1002/ccr3.5629http://dx.doi.org/10.1002/ccr3.5629.
Hallsworth D, Thompson J, Wilkinson D, et al. Intracranial pressure monitoring and caesarean section in a patient with von Hippel-Lindau disease and symptomatic cerebellar haemangioblastomas. Int J Obstet Anesth 2015; 24(1): 73-7. doi: 10.1016/j.ijoa.2014.08.008http://dx.doi.org/10.1016/j.ijoa.2014.08.008.
Adekola H, Soto E, Lam J, et al. von Hippel-Lindau disease and pregnancy: what an obstetrician should know. Obstet Gynecol Surv 2013; 68(9): 655-62. doi:10.1097/OGX.0b013e3182a85063http://dx.doi.org/10.1097/OGX.0b013e3182a85063.
Castinetti F, Moley J, Mulligan L, et al. A comprehensive review on MEN2B. Endocr. Relat. Cancer 2018; 25(2): T29-39. doi:10.1530/erc-17-0209http://dx.doi.org/10.1530/erc-17-0209.
Mathiesen JS, Effraimidis G, Rossing M, et al. Multiple endocrine neoplasia type 2: a review. Semin Cancer Biol 2022; 79: 163-79. doi: 10.1016/j.semcancer.2021.03.035http://dx.doi.org/10.1016/j.semcancer.2021.03.035.
Jr.Wells SA, Asa SL, Dralle H, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25(6): 567-610. doi:10.1089/thy.2014.0335http://dx.doi.org/10.1089/thy.2014.0335.
Al-Salameh A, Baudry C, Cohen R. Update on multiple endocrine neoplasia type 1 and 2. Presse Med 2018; 47(9): 722-31. doi:10.1016/j.lpm.2018.03.005http://dx.doi.org/10.1016/j.lpm.2018.03.005.
Jr.Wells SA, Pacini F, Robinson BG, et al. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab 2013; 98(8): 3149-64. doi:10.1210/jc.2013-1204http://dx.doi.org/10.1210/jc.2013-1204.
Scholten A, Vriens MR, Cromheecke GJ, et al. Hemodynamic instability during resection of pheochromocytoma in MEN versus non-MEN patients. Eur J Endocrinol 2011; 165(1): 91-6. doi:10.1530/eje-11-0148http://dx.doi.org/10.1530/eje-11-0148.
Ma L, Shen L, Zhang X, et al. Predictors of hemodynamic instability in patients with pheochromocytoma and paraganglioma. J Surg Oncol 2020; 122(4): 803-8. doi:10.1002/jso.26079http://dx.doi.org/10.1002/jso.26079.
Foo CW, Chen XY, Kumar CM. Anaesthetic management for laparoscopic bilateral adrenalectomy in MEN2A (multiple endocrine neoplasia) followed by subsequent total thyroidectomy and radical neck dissection. Br J Anaesth 2015; 114(4): 700-1. doi:10.1093/bja/aev059http://dx.doi.org/10.1093/bja/aev059.
Li Y, Jin D, Shen L, et al. Anesthesia and outcome of 33 surgeries in 24 multiple endocrine neoplasia type 2a (MEN2A) patients: a national rare disease center's experience. Front Endocrinol (Lausanne) 2022; 13: 905963. doi:10.3389/fendo.2022.905963http://dx.doi.org/10.3389/fendo.2022.905963.
Fuller S, Del Rivero J, Venzon D, et al. Pulmonary function in patients with multiple endocrine neoplasia 2b. J Clin Endocrinol Metab 2020; 105(9): 2919-28 .doi:10.1210/clinem/dgaa296http://dx.doi.org/10.1210/clinem/dgaa296.
Fareez F, Wang BH, Brain I, et al. Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome? Pathology 2023; 55(3): 302-14. doi: 10.1016/j.pathol.2023.01.002http://dx.doi.org/10.1016/j.pathol.2023.01.002.
Saleh M, Dib A, Beaini S, et al. Neurofibromatosis type 1 system-based manifestations and treatments: a review. Neurol Sci 2023; 44(6): 1931-47. doi:10.1007/s10072-023-06680-5http://dx.doi.org/10.1007/s10072-023-06680-5.
Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007; 44(2): 81-8. doi:10.1136/jmg.2006.045906http://dx.doi.org/10.1136/jmg.2006.045906.
Gutmann DH, Ferner RE, Listernick RH, et al. Neurofibromatosis type 1. Nat Rev Dis Primers 2017; 3: 17004. doi:10.1038/nrdp.2017.4http://dx.doi.org/10.1038/nrdp.2017.4.
Bergqvist C, Servy A, Valeyrie-Allanore L, et al. Neurofibromatosis 1 french national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis 2020; 15(1): 37. doi:10.1186/s13023-020-1310-3http://dx.doi.org/10.1186/s13023-020-1310-3.
Theodosopoulou P, Nastos C, Paraskeva A. Anesthetic management of a patient with type 1 neurofibromatosis and an occult pheochromocytoma: a case report. Braz J Anesthesiol 2023; 73(5): 695-8. doi:10.1016/j.bjane.2021.02.045http://dx.doi.org/10.1016/j.bjane.2021.02.045.
Walther M, Herring J, Enquist E, et al. von Recklinghausen's disease and pheochromocytomas. J Urol 1999; 162(5): 1582-6..
Butz JJ, Yan Q, McKenzie TJ, et al. Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1. Surgery 2017; 162(6): 1259-69. doi:10.1016/j.surg.2017.08.002http://dx.doi.org/10.1016/j.surg.2017.08.002.
Hirsch NP, Murphy A, Radcliffe JJ. Neurofibromatosis: clinical presentations and anaesthetic implications. Br J Anaesth 2001; 86(4): 555-64. doi:10.1093/bja/86.4.555http://dx.doi.org/10.1093/bja/86.4.555.
Guerrero-Domínguez R, López-Herrera-Rodríguez D, Acosta-Martínez J, et al. Implicaciones anestésicas en la enfermedad de Von Recklinghausen. Rev Colomb Anestesiol 2015; 43(1): 107-10. doi:https://doi.org/10.1016/j.rca.2014.08.002https://doi.org/10.1016/j.rca.2014.08.002.
Nakazawa R, Masui K, Goto T. Anesthesia management for thoracoscopic resection of a huge intrathoracic meningocele: a case report. JA Clin Rep 2024; 10(1): 14. doi:10.1186/s40981-024-00697-1http://dx.doi.org/10.1186/s40981-024-00697-1.
Lee JA, Duh Q-Y. Sporadic paraganglioma. World J Surg 2008; 32(5): 683-7. doi:10.1007/s00268-007-9360-4http://dx.doi.org/10.1007/s00268-007-9360-4.
Sharma S, Fishbein L. Diagnosis and management of pheochromocytomas and paragangliomas: a guide for the clinician. Endocr Pract 2023; 29(12): 999-1006. doi: 10.1016/j.eprac.2023.07.027http://dx.doi.org/10.1016/j.eprac.2023.07.027.
Bracigliano A, Marretta AL, Guerrera LP, et al. The management of phaeochromocytomas and paragangliomas in the era of precision medicine: where are we now? Evidence-based systemic treatment options and future cluster oriented perspectives. Pharmaceuticals (Basel) 2024; 17(3): 354. doi:10.3390/ph17030354http://dx.doi.org/10.3390/ph17030354.
Nölting S, Bechmann N, Taieb D, et al. Personalized management of pheochromocytoma and paraganglioma. Endocr Rev 2022; 43(2): 199-239. doi:10.1210/endrev/bnab019http://dx.doi.org/10.1210/endrev/bnab019.
Foo SH, Chan SP, Ananda V, et al. Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management. Singapore Med J 2010; 51(5): e8993..
Publicity Resources
Related Articles
Related Author
Related Institution
- © 2024 Chinese Academy of Medical Sciences 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.